Research Analysts Set Expectations for Korro Bio Q3 Earnings

Key Points

• HC Wainwright has revised Korro Bio's Q3 2025 EPS estimate downward from ($1.88) to ($2.43), while maintaining a "Buy" rating with a $90.00 price target.
• In its latest quarterly earnings report, Korro Bio reported an EPS of ($2.74), missing estimates, but exceeded revenue expectations with $1.46 million against a forecast of $0.41 million.
• Korro Bio has received mixed reviews from analysts; while five have given a buy rating, others have reduced their price targets significantly, with the average target now at $86.83.

Korro Bio, Inc. (NASDAQ:KRRO - Free Report) - Stock analysts at HC Wainwright reduced their Q3 2025 earnings estimates for Korro Bio in a research report issued on Wednesday, August 13th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of ($2.43) for the quarter, down from their previous forecast of ($1.88). HC Wainwright has a "Buy" rating and a $90.00 price objective on the stock. The consensus estimate for Korro Bio's current full-year earnings is ($9.52) per share. HC Wainwright also issued estimates for Korro Bio's Q4 2025 earnings at ($2.26) EPS, FY2025 earnings at ($9.93) EPS, Q1 2026 earnings at ($2.23) EPS, Q2 2026 earnings at ($2.28) EPS, Q3 2026 earnings at ($2.34) EPS, Q4 2026 earnings at ($2.39) EPS and FY2026 earnings at ($9.23) EPS.

Other research analysts have also issued research reports about the company. Cantor Fitzgerald upgraded Korro Bio to a "strong-buy" rating in a research report on Tuesday, April 29th. Raymond James Financial dropped their target price on shares of Korro Bio from $153.00 to $147.00 and set a "strong-buy" rating on the stock in a research report on Wednesday, August 13th. Chardan Capital reissued a "buy" rating and set a $25.00 target price on shares of Korro Bio in a research report on Wednesday, August 13th. Finally, Oppenheimer reduced their price objective on Korro Bio from $155.00 to $90.00 and set an "outperform" rating for the company in a research note on Tuesday, May 13th. Two equities research analysts have rated the stock with a Strong Buy rating and five have given a Buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Buy" and an average price target of $86.83.

Korro Bio Price Performance

Shares of KRRO stock traded up $0.09 during trading hours on Friday, reaching $19.23. 22,652 shares of the company traded hands, compared to its average volume of 114,534. The firm has a 50-day moving average price of $14.48 and a 200 day moving average price of $17.81. Korro Bio has a 12-month low of $10.29 and a 12-month high of $98.00. The company has a market cap of $180.57 million, a P/E ratio of -1.97 and a beta of 2.51.

Korro Bio (NASDAQ:KRRO - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($2.74) EPS for the quarter, missing the consensus estimate of ($2.54) by ($0.20). The business had revenue of $1.46 million during the quarter, compared to analyst estimates of $0.41 million.

Hedge Funds Weigh In On Korro Bio

Several institutional investors have recently made changes to their positions in the company. Deep Track Capital LP increased its holdings in shares of Korro Bio by 2.9% during the 4th quarter. Deep Track Capital LP now owns 874,614 shares of the company's stock valued at $33,297,000 after purchasing an additional 24,614 shares in the last quarter. Driehaus Capital Management LLC lifted its position in shares of Korro Bio by 17.7% during the 1st quarter. Driehaus Capital Management LLC now owns 582,449 shares of the company's stock valued at $10,140,000 after buying an additional 87,544 shares in the last quarter. Point72 Asset Management L.P. grew its stake in Korro Bio by 11.0% in the 4th quarter. Point72 Asset Management L.P. now owns 493,997 shares of the company's stock valued at $18,806,000 after acquiring an additional 49,147 shares during the period. Cormorant Asset Management LP acquired a new stake in Korro Bio in the 1st quarter valued at $6,621,000. Finally, Geode Capital Management LLC grew its stake in Korro Bio by 10.8% in the 2nd quarter. Geode Capital Management LLC now owns 155,387 shares of the company's stock valued at $1,941,000 after acquiring an additional 15,166 shares during the period. 13.18% of the stock is owned by hedge funds and other institutional investors.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).